The benefits and risks of escalation versus early highly effective treatment in patients with multiple sclerosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The benefits and risks of escalation versus early highly effective treatment in patients with multiple sclerosis

Published:2023-05-04 Issue:5 Volume:23 Page:433-444
ISSN:1473-7175
Container-title:Expert Review of Neurotherapeutics
language:en
Short-container-title:Expert Review of Neurotherapeutics

Author:

Morgan Annalisa¹,Tallantyre Emma²³,Ontaneda Daniel¹⁴^ORCID

Affiliation:

1. Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA

2. Division of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, UK

3. Department of Neurology, University Hospital of Wales, Cardiff, UK

4. Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Neurology (clinical),General Neuroscience

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737175.2023.2208347

Reference95 articles.

1. Disease modifying therapies for relapsing multiple sclerosis

2. Diagnosis and Treatment of Multiple Sclerosis

3. Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis

4. Managing Multiple Sclerosis: Treatment Initiation, Modification, and Sequencing

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perceived illness-related uncertainty among patients with mid-stage relapsing-remitting multiple sclerosis;Multiple Sclerosis and Related Disorders;2024-11

2. Clinical practice guidelines for multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease 2023 in Japan;Multiple Sclerosis and Related Disorders;2024-10

3. Benefits of early highly effective versus escalation treatment strategies in relapsing multiple sclerosis estimated using a treatment-sequence model;Multiple Sclerosis Journal;2024-06-10

4. Decisional Conflict Regarding Disease-Modifying Treatment Choices Among Patients with Mid-Stage Relapsing-Remitting Multiple Sclerosis;Patient Preference and Adherence;2024-06

5. Substantial and comparable suppression of disease activity following early initiation of cladribine tablets, ocrelizumab or alemtuzumab as first pharmacologic treatment for relapsing multiple sclerosis: A real world study;Clinical Neurology and Neurosurgery;2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3